Chad vs Papua New Guinea: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Chad
2.2%
in 2024
Papua New Guinea
2.5%
in 2024
Chad rank
13th
Papua New Guinea rank
11th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Chad
- Papua New Guinea
How they compare
Papua New Guinea currently reports 2.5% against 2.2% in Chad, a difference of 0.3%.
That makes Papua New Guinea's figure about 1.1 times Chad's.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Chad ahead.
Chad ranks 13th and Papua New Guinea ranks 11th of 246 countries.
Chad has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Chad | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4.1% | 2.0% | 2.2% | Chad |
| 2020s | 3.0% | 2.4% | 0.6% | Chad |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Chad or Papua New Guinea?
- Papua New Guinea, at 2.5% against 2.2% in Chad as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Chad and Papua New Guinea?
- 0.3%, with Papua New Guinea ahead.
- How many years of comparable data are there for Chad and Papua New Guinea?
- 10 years are reported by both, from 2015 to 2024.
- How do Chad and Papua New Guinea rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Chad ranks 13th and Papua New Guinea ranks 11th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.